Education
About Us
Working with TipRanks
Follow Us
Sionna Therapeutics, Inc. (SION)
NASDAQ:SION
SION Analyst Ratings
Moderate Buy
6 Buy
0 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SION Stock 12 Month Forecast
Average Price Target
$51.17
▲(37.66% Upside)
| Highest Price Target$63.00 | Average Price Target$51.17 | Lowest Price Target$24.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
$60
Buy
61.42%
Upside
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (NASDAQ: SION) and Health Catalyst (NASDAQ: HCAT)Last week, we hosted a live webinar with KOL Ruchi Gupta, PhD, where we discussed cysc fibrosis (CF), the unmet need that remains with the current SoC, NBD1 biology and mechanisc/ clinical raonale, and Sionna’s CFHBE model/assay data package across their NBD1 stabilizers. As a reminder, PreciSION trial is ongoing, adding SION-719 (NBD1 stabilizer) to Trikaa (SoC) in F508del- homozygous CF, with topline data expected MY 2026. Sionna is also conducng a dual combo Phase 1 HV trial with SION-451 (NBD1 stabilizer) + with topline data expected MY 2026. Key takeaways include (more within): KOL notes that NBD1 domain is difficult to experimentally express and stabilize, lacks clear allosteric binding pockets, and contains an ATP-binding site that is unsuitable to target because inhibing ATP binding would impair channel funcon.
JonesTrading
$52
Buy
39.90%
Upside
Reiterated
03/06/26
TD Cowen
―
Buy
―
Reiterated
03/02/26
Guggenheim
$45→$50
Buy
34.52%
Upside
Reiterated
03/02/26
RBC Capital
$24
Sell
-35.43%
Downside
Reiterated
03/02/26
BTIG
$58
Buy
56.04%
Upside
Reiterated
03/02/26
Citizens JMP
$63
Buy
69.49%
Upside
Initiated
02/24/26
Stifel Nicolaus
$32
Buy
-13.91%
Downside
Reiterated
05/14/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
$60
Buy
61.42%
Upside
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (NASDAQ: SION) and Health Catalyst (NASDAQ: HCAT)Last week, we hosted a live webinar with KOL Ruchi Gupta, PhD, where we discussed cysc fibrosis (CF), the unmet need that remains with the current SoC, NBD1 biology and mechanisc/ clinical raonale, and Sionna’s CFHBE model/assay data package across their NBD1 stabilizers. As a reminder, PreciSION trial is ongoing, adding SION-719 (NBD1 stabilizer) to Trikaa (SoC) in F508del- homozygous CF, with topline data expected MY 2026. Sionna is also conducng a dual combo Phase 1 HV trial with SION-451 (NBD1 stabilizer) + with topline data expected MY 2026. Key takeaways include (more within): KOL notes that NBD1 domain is difficult to experimentally express and stabilize, lacks clear allosteric binding pockets, and contains an ATP-binding site that is unsuitable to target because inhibing ATP binding would impair channel funcon.
JonesTrading
$52
Buy
39.90%
Upside
Reiterated
03/06/26
TD Cowen
―
Buy
―
Reiterated
03/02/26
Guggenheim
$45→$50
Buy
34.52%
Upside
Reiterated
03/02/26
RBC Capital
$24
Sell
-35.43%
Downside
Reiterated
03/02/26
BTIG
$58
Buy
56.04%
Upside
Reiterated
03/02/26
Citizens JMP
$63
Buy
69.49%
Upside
Initiated
02/24/26
Stifel Nicolaus
$32
Buy
-13.91%
Downside
Reiterated
05/14/25
Best Analysts Covering Sionna Therapeutics, Inc.
3 Months
xxx
Success Rate
6/6 ratings generated profit
Average Return
+40.08%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +40.08% per trade.
1 Year
Success Rate
6/6 ratings generated profit
Average Return
+115.45%
reiterated a buy rating 16 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +115.45% per trade.
2 Years
xxx
Success Rate
6/6 ratings generated profit
Average Return
+118.55%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +118.55% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SION Analyst Recommendation Trends
Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
1
0
1
3
6
Buy
4
8
8
7
6
Hold
2
1
2
4
22
Sell
0
2
2
4
6
Strong Sell
0
0
0
0
0
total
7
11
13
18
40
Each month's total comprises the sum of three months' worth of ratings.
SION Financial Forecast
SION Stock Forecast FAQ
What is SION’s average 12-month price target, according to analysts?
Based on analyst ratings, Sionna Therapeutics, Inc.’s 12-month average price target is 51.17.
What is SION’s upside potential, based on the analysts’ average price target?
Sionna Therapeutics, Inc. has 37.66% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SION a Buy, Sell or Hold?
Sionna Therapeutics, Inc. has a consensus rating of Moderate Buy which is based on 6 buy ratings, 0 hold ratings and 1 sell ratings.
What is Sionna Therapeutics, Inc.’s price target?
The average price target for Sionna Therapeutics, Inc. is 51.17. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $63.00 ,the lowest forecast is $24.00. The average price target represents 37.66% Increase from the current price of $37.17.
The highest analyst price target is $63.00 ,the lowest forecast is $24.00. The average price target represents 37.66% Increase from the current price of $37.17.
What do analysts say about Sionna Therapeutics, Inc.?
Sionna Therapeutics, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of SION?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.